XML Template (2009) [7.9.2009–9:27am] [1–14]
{TANDF_FPP}CMO/CMO_A_370737(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
b.i.d.
mg
mg
50 9.4 6 49
1000
157
¼
C6 (41) C6
(6.6–11.2)
C6
4.4
2
C6
0.9
(continuation
MF
N
65
53.6
C6
195 4.6
Sitagliptin
þ
8.7
phase b.i.d.
b.i.d.
mg
50
mg
10.0
73 47
placebo-controlled 500
148
¼
C6
(53) C6 (6.8–11.0) C6
4.4
2
C6
MF
N
78
1.0
week C6
198 4.1
Sitagliptin
þ
53.7
24- 8.8
b.i.d.
initial
the
b.i.d.
during
mg
9.5 73 43
137
1000
C6 (45) C6
(6.9–10.9)
C6
4.0
therapy
¼ 2
C6
N
62
54.2
0.8
C6
188 4.1
rescue
8.5
Metformin
glycemic
122
¼
N
9.9 73 41
initiating C6 (48) C6
(7.2–11.0)
C6
3.8
C6
b.i.d.
Metformin
58
2
1.0
mg
53.7
C6
189 4.1
without
500
8.7
mellitus.
phase
diabetes
q.d.
2
mg
continuation
9.1 63 39
type
100
106
(7.2–11.4)
¼
C6 (52) C6 C6
4.6
C6
N
55
1
53.5
1.0
T2DM,
30-week
C6
183 3.9
[%]).
(
n
8.7
the
Sitagliptin
glucose;
frequency
entered
or
plasma
b.i.d.
who
mg
fasting
78
11.3
73 41 deviation
(7.0–10.6)
C6
5.0
patients
1000
¼
C6
(49) C6
C6
FPG,
of
N 38 32
0.9
53.6
C6
174 3.8
standard
index;
8.4
C6
mass
Placebo/MF
mean
as
body
characteristics
BMI,
T2DM,
(%)
2
Baseline
of
n
expressed
2.
years kg/m
,%(range)
mg/dL years
population).
1c
are
metformin;
Parameter Age, Males, BMI, HbA FPG, Duration Data MF,
Table APT
6
54-week efficacy and safety of sitagliptin/metformin Williams-Herman et al. www.cmrojournal.com
!
2009 Informa UK Ltd
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34